Investment Rating - The investment rating for the company is "Accumulate" [6] Core Views - The company reported a revenue of 762 million yuan for 2024, representing a year-on-year increase of 14.4%, and a net profit of 254 million yuan, which is a significant year-on-year growth of 74.6%. The high profit growth is driven by breakthroughs in overseas business, increased market share of key domestic products, and optimized expense ratios [1][5] - The company is expected to maintain a high net profit margin in 2025, despite potential short-term pressure on domestic revenue due to centralized procurement impacts [1][4] Summary by Sections Growth Potential - Domestic revenue may face short-term pressure due to centralized procurement impacts on hemorrhagic products, which saw a revenue of 402 million yuan in 2024, down 5.5% year-on-year. However, ischemic/narrowing products are expected to continue growing, with revenue from atherosclerotic narrowing products reaching 268 million yuan, up 74.6% year-on-year [2] - The acute ischemic product segment is projected to maintain high growth, with revenue of 47 million yuan in 2024, up 82.0% year-on-year, driven by new product launches [2] International Expansion - The company achieved overseas revenue of 75 million yuan in 2024, a remarkable increase of 137.6% year-on-year, marking its first year of profitability in international markets. The company has commercialized eight products across 30 countries and regions [3] Profitability - The gross profit margin is expected to remain around 70%. In 2024, the gross profit margin was 73.0%, a decrease of 3.9 percentage points year-on-year, primarily due to the decline in revenue from hemorrhagic products and price reductions from centralized procurement [4] - The net profit margin reached 32.7% in 2024, a significant increase of 12.5 percentage points year-on-year, and is expected to maintain around 30% in 2025 due to ongoing cost reduction and efficiency improvement strategies [4] Financial Forecast and Investment Recommendations - Revenue projections for 2025-2027 are 828 million yuan, 1.002 billion yuan, and 1.197 billion yuan, representing year-on-year growth rates of 8.72%, 20.95%, and 19.49% respectively. Net profit forecasts are 256 million yuan, 321 million yuan, and 384 million yuan, with corresponding year-on-year growth rates of 0.67%, 25.48%, and 19.74% [5][11]
微创脑科学（02172）：2024年年报点评：高利润率有望持续